Last reviewed · How we verify
Xenical
Xenical is a Small molecule drug developed by Khoo Teck Puat Hospital. It is currently FDA-approved for Obesity. Also known as: Orlistat.
At a glance
| Generic name | Xenical |
|---|---|
| Also known as | Orlistat |
| Sponsor | Khoo Teck Puat Hospital |
| Target | Abhydrolase domain-containing protein 16A, Endothelial lipase, Fatty acid synthase |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Obesity
Common side effects
- Oily spotting
- Flatus with discharge
- Fecal urgency
- Fatty/oily stool
- Oily evacuation
- Increased defecation
- Fecal incontinence
- Gastrointestinal symptoms
- Hypoglycemia
- Abdominal distension
Serious adverse events
- Hepatic failure
- Hepatitis
- Increased transaminases
- Increased alkaline phosphatase
- Hypersensitivity reactions
- Angioedema
- Urticaria
- Rash
- Pruritus
Key clinical trials
- RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. (PHASE4)
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity (PHASE2)
- Effect of Electroacupuncture on Central Obesity and Fatty Liver in Postmenopausal Women (NA)
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America (PHASE4)
- A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
- Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT (NA)
- Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) (PHASE4)
- Weight Loss Management in Endometrial Cancer Survivors
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xenical CI brief — competitive landscape report
- Xenical updates RSS · CI watch RSS
- Khoo Teck Puat Hospital portfolio CI
Frequently asked questions about Xenical
What is Xenical?
Xenical is a Small molecule drug developed by Khoo Teck Puat Hospital, indicated for Obesity.
What is Xenical used for?
Xenical is indicated for Obesity.
Who makes Xenical?
Xenical is developed and marketed by Khoo Teck Puat Hospital (see full Khoo Teck Puat Hospital pipeline at /company/khoo-teck-puat-hospital).
Is Xenical also known as anything else?
Xenical is also known as Orlistat.
What development phase is Xenical in?
Xenical is FDA-approved (marketed).
What are the side effects of Xenical?
Common side effects of Xenical include Oily spotting, Flatus with discharge, Fecal urgency, Fatty/oily stool, Oily evacuation, Increased defecation. Serious adverse events: Hepatic failure, Hepatitis, Increased transaminases, Increased alkaline phosphatase.
What does Xenical target?
Xenical targets Abhydrolase domain-containing protein 16A, Endothelial lipase, Fatty acid synthase.
Related
- Target: All drugs targeting Abhydrolase domain-containing protein 16A, Endothelial lipase, Fatty acid synthase
- Manufacturer: Khoo Teck Puat Hospital — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Obesity
- Also known as: Orlistat